

**SERIAL NO.**

REV 7-00

**ELN-002**

**10/010942**

### LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

**APPLICANT**

Basi, Guriq et al.

FILING DATE

**December 6, 2001**

**GROUP**

1995

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
✓	B1	JP 7-165799	06/95	Japan			Abstract Only	
✓	B2	WO 00/23082 A1	04/00	WO				
✓	B3	WO 00/72880 A2,A3	05/00	WO				
✓	B4	WO 02/088306 A2	11/02	WO				
✓	B5	WO 02/088307 A2	11/02	WO				

**OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)**

[illegible]

**Examiner**

**Date Considered**

\*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/ST/08A (08-00)  
OCT 07 2002  
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) in this box ☐

PTO/ST/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 16

## Complete If Known

Application Number 10/010942  
Filing Date December 6, 2001  
First Named Inventor Basi, Guriq et al.  
Group Art Unit 1645-1647  
Examiner Name NICHOLS  
Attorney Docket Number ELN-002

OCT 15 2002  
RECEIVED  
CH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CWO	283	09/441,140		Solomon et al.	11-16-1999	
	242	60/168,594		Chaffour et al.	N/A	
	282	60/169,687		Chain	N/A	
	205	60/184,601		Holtzman et al.	N/A	
	289	60/186,265		Rasmussen et al.	N/A	
	290	60/254,466		Holtzman et al.	N/A	
	297	60/254,498		Holtzman et al.	N/A	
	300	2001/0018053	A1	McMichael	08-30-2001	
	267	6,294,171	B2	McMichael	09-25-2001	
	234	6,284,221	B1	Schenk, et al.	09-04-2001	
	230	6,262,335	B1	Hsiao et al.	07-17-2001	
	231	6,114,133		Seubert et al.	09-05-2000	
	186	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	221	5,989,566		Cobb et al.	11-23-1999	
	2	5,958,883		Snow	09-28-1999	
	3	5,955,317		Suzuki et al.	09-21-1999	
V	4	5,955,079		Mond et al.	09-21-1999	
	5	5,877,399		Hsiao et al.	03-02-1999	
	6	5,889,093		Weiner et al.	02-09-1999	
	7	5,869,054		Weiner et al.	02-09-1999	
	8	5,854,204		Findeis et al.	12-28-1998	
	9	5,851,996		Kline	12-22-1998	
	10	5,849,298		Weiner et al.	12-15-1998	
	11	5,837,473		Maggio et al.	11-17-1998	
	12	5,786,180		Konig et al.	07-28-1998	
	207	5,780,587		Potter	07-14-1998	
CWO	13	5,753,624		McMichael et al.	05-18-1998	
	14	5,750,349		Suzuki et al.	05-12-1998	
	197	5,744,368		Goldgaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	15	5,733,547		Weiner et al.	03-31-1998	
	16	5,688,651		Solomon	11-18-1997	
	17	5,679,348		Nesburn et al.	10-21-1997	

INTENTION OF CITATIONS

Examiner Signature	<i>Guriq</i>	Date Considered	5/14/04
--------------------	--------------	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v21



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 16

### Complete If Known

Application Number 10/010942  
Filing Date December 6, 2001  
First Named Inventor Basi, Guriq *et al.*  
Group Art Unit 1645 1647  
Examiner Name NICHOLS  
Attorney Docket Number ELN-002

TECH CENTER 600/2900

OCT 15 2002

RECEIVED

18	5,645,820	Hafler et al.	07-08-1997
19	5,641,474	Hafler et al.	06-24-1997
20	5,641,473	Hafler et al.	06-24-1997
21	5,612,486	McConlogue et al.	03-18-1997
22	5,605,811	Seubert et al.	02-25-1997
23	5,585,100	Mond et al.	12-17-1996
24	5,571,500	Hafler et al.	11-05-1996
25	5,571,499	Hafler et al.	11-05-1996
175	5,441,870	Seubert, et al.	08-15-1995
26	5,434,170	Andrulis, Jr.	07-18-1995
27	5,387,742	Cordell	02-07-1995
181	5,270,165	Van Nostrand et al.	12-14-1993
284	5,231,170	Averback	1993-07-27
28	5,231,000	Majocha et al.	07-27-1993
29	5,220,013	Ponte et al.	08-15-1993
30	5,208,036	Eppstein et al.	05-04-1993
31	5,192,753	McGeer et al.	03-09-1993
32	5,187,153	Cordell et al.	02-16-1993
33	5,057,540	Kensil et al.	10-15-1991
198	5,004,697	Pardridge	04-02-1991
34	4,666,829	Glenner et al.	05-18-1987

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
20	35	EP	911 036	A2		04-28-1999		
	36	EP	868 918	A2		10-07-1998		
	37	EP	863 211	A1		09-09-1998		
	38	EP	845 270	A1		08-03-1998		
	39	EP	782 859	A1		07-09-1997		
	40	EP	683 234	A1		11-22-1995		
	41	EP	668 080	A1		08-09-1995		
	42	EP	652 862	B1		12-16-1998		
	43	EP	639 081	B1		11-03-1999		
	44	EP	613 007	A2		08-31-1994		
	45	EP	594 607	B1		08-27-1997		
	46	EP	561 087	B1		08-04-1999		
	47	EP	526 511	B1		05-28-1997		
20	48	EP	506 785	B1		03-15-2000		

Examiner Signature

*G. Williams*

Date Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

16

## Complete If Known

Application Number

10/010942

Filing Date

December 6, 2001

First Named Inventor

Basi, Guriq *et al.*

Group Art Unit

1645-1647

Examiner Name

NICHOLS

Attorney Docket Number

ELN-002

OCT 15 2002

RECEIVED

49	EP	451 700	A1		10-18-1991		
50	EP	440 819	B1		01-24-1996		
51	EP	359 783	B1		11-29-1995		
52	EP	276 723	B1		12-08-1993		Yes
187	EP	783 104	A1		07-08-1997		
294	PCT	01/62801	A2		08-30-2001		
301	PCT	01/62284	A2		03-01-2000		
298	PCT	01/42306	A2		08-14-2001		
243	PCT	01/39796	A2		06-07-2001		
199	PCT	00/77178	A1		12-21-2000		
240	PCT	00/43039	A1		07-27-2000		
188	PCT	00/43049	A1		07-27-2000		
53	PCT	99/60024	A1		11-25-1999		
54	PCT	99/60021	A2		11-15-1999		
55	PCT	99/58564	A1		11-18-1999		
56	PCT	99/06066	A2		02-11-1999		
57	PCT	99/27949	A1		06-10-1999		
58	PCT	99/27944	A1		06-10-1999		
59	PCT	99/27911	A1		06-10-1999		
203	PCT	99/00150	A2		01-07-1999		
60	PCT	98/44955	A1		10-15-1998		
61	PCT	98/07850	A2		02-28-1998		
202	PCT	97/21728	A1		08-19-1997		
62	PCT	97/17613	A1		05-15-1997		
63	PCT	96/39176	A1		12-12-1996		
208	PCT	96/28471	A1		09-19-1996		
64	PCT	96/25435	A1		08-22-1996		
65	PCT	96/18900	A1		08-20-1996		
66	PCT	95/31998	A1		11-30-1995		
200	PCT	95/12815	A1		05-11-1995		
67	PCT	95/11894	A1		05-04-1995		
68	PCT	95/11311	A1		04-27-1995		
227	PCT	95/11008	A2		04-27-1995		
69	PCT	95/05853	A1		03-02-1995		
70	PCT	95/04151	A2		02-09-1995		
201	PCT	94/28412	A1		12-08-1994		
71	PCT	94/03815	A1		02-17-1994		
72	PCT	94/01772	A1		01-20-1994		
73	PCT	93/21950	A1		11-11-1993		
74	PCT	93/16724	A1		09-02-1993		
75	PCT	93/15760	A1		08-18-1993		

Examiner  
Signature

*G. Nichols*

Date  
Considered

5/14/04

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23

PE J0555  
OCT 07 2002  
PATENT & TRADEMARK

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 16

## Complete If Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq et al.
Group Art Unit	1645-1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

RECEIVED  
OCT 15 2002


76	PCT	93/14200	A1	07-22-1993
205	PCT	93/04194	A1	03-04-1993
77	PCT	93/02189	A1	02-04-1993
78	PCT	92/13069	A1	08-08-1992
79	PCT	92/06708	A1	04-30-1992
80	PCT	92/06187	A1	04-18-1992
81	PCT	91/19810	A1	12-28-1991
82	PCT	91/16819	A1	11-14-1991
83	PCT	91/12816	A1	09-05-1991
84	PCT	91/08760	A1	08-27-1991
85	PCT	90/12871	A1	11-01-1990
86	PCT	90/12870	A1	11-01-1990
87	PCT	89/01343	A1	02-23-1989
88	PCT	89/08242	A1	07-13-1989
89	PCT	89/06889	A1	07-27-1989
90	PCT	89/03887	A1	05-05-1989
91	PCT	88/10120	A1	12-29-1988
92	GB	2 220 211	A	01-04-1990
93	GB	2 335 192	A	09-15-1999

Examiner Signature		Date Considered	5/14/04
--------------------	--	-----------------	---------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 16

### Complete if Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Guriq, Basi <i>et al.</i>
Group Art Unit	1645 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

TECH CENTER 1601/2500  
OCT 15 2002

RECEIVED

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <i>Neurology</i> , 45:1441-1445 (1995).	<input type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95).	<input type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8):916-919 (2000).	<input type="checkbox"/>
	228	BARROW, et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J. Mol. Biol.</i> , 225(4): 1075-1093 (1992).	<input type="checkbox"/>
	96	BAUER et al., "Interleukin-6 and $\alpha$ -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991).	<input type="checkbox"/>
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	<input type="checkbox"/>
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> , 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:764 (1992).	<input type="checkbox"/>
	97	BLASS, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).	<input type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).	<input type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <i>Neuron</i> , 19: 939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <i>Cur. Opin. Genet. Develop.</i> , 3: 102-109 (1993).	<input type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 58:112-115 (1993).	<input type="checkbox"/>
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <i>Clin. Neuropharm.</i> , 15:414A-414B (1992).	<input type="checkbox"/>
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : <a href="http://www.fda.gov/cber/vaccine/thimerosal.htm">http://www.fda.gov/cber/vaccine/thimerosal.htm</a> , last updated May 18, 2002.	<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3147648 v21



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 16

### Complete If Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Gurig <i>et al.</i>
Group Art Unit	1645 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

102	CHAO et al., "Transforming Growth Factor- $\beta$ Protects human Neurons Against $\beta$ -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513.7 (1993).	<input type="checkbox"/>
266	CHAPMAN, PAUL F., "Model behavior," <u>Nature</u> , 408:915-916 (2000).	<input type="checkbox"/>
<del>222</del>	<del>Chemical Abstract database. Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals," Chemical Abstract database. (Publication date unknown.)</del>	<input type="checkbox"/>
213	CHEN et al., "An Antibody to $\beta$ Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> 125:223-226 (1991).	<input type="checkbox"/>
302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid $\beta$ -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).	<input type="checkbox"/>
291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).	<input type="checkbox"/>
286	CORDELL, B., " $\beta$ -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).	<input type="checkbox"/>
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).	<input type="checkbox"/>
293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).	<input type="checkbox"/>
214	DEMATTOS et al., "Peripheral Anti A $\beta$ Antibody Alters CNS And Plasma A $\beta$ Clearance and Decreases Brain A $\beta$ Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).	<input type="checkbox"/>
<del>220</del>	<del>Dialog/Derwent. Abstract of WPI ACC No. 1997-034436/199706. Stable vaccine compns. - comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water, Derwent File 354: Derwent WPI database. (Publication date unknown.)</del>	<input type="checkbox"/>
103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).	<input type="checkbox"/>
288	DUMERY et al., " $\beta$ -Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).	<input type="checkbox"/>
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/28/2002).	<input type="checkbox"/>
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	<input type="checkbox"/>
104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).	<input type="checkbox"/>
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?," <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).	<input type="checkbox"/>

Examiner  
Signature

*[Signature]*

Date  
Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23

OCT 15 2002

PRINTED ON OCT 15 2002





Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 16

### Complete if Known

Application Number 10/010942  
Filing Date December 6, 2001  
First Named Inventor Basi, Guriq *et al.*  
Group Art Unit 1645-1647  
Examiner Name NICHOLS  
Attorney Docket Number ELN-002

RECEIVED  
OCT 15 2002  
TECH CENTER 1600 2909

105	FELSENSTEIN et al., "Processing of the $\beta$ -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	1
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).	1
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	1
108	FLANDERS et al., "Altered expression of transforming growth factor- $\beta$ in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).	1
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	1
247	FRENKEL et al., "Immunization against Alzheimer's $\beta$ -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).	1
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's $\beta$ -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).	1
245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of $\beta$ -amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999).	1
244	FRENKEL, et al., "Modulation of Alzheimer's $\beta$ -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000).	1
210	FRIEDLAND et al., "Development of an anti-A $\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).	1
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).	1
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	1
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A $\beta$ <sub>1-42</sub> ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).	1
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).	1
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990).	1
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1188 (1993).	1
252	GEDDES, "N-terminus truncated $\beta$ -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).	1
253	GIULIAN, et al., "The HHQK Domain of $\beta$ -Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).	1

Examiner  
Signature

*G. Nichols*

Date  
Considered

5/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23



Please type a plus sign (+) inside this box




PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 16

## Complete If Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq et al.
Group Art Unit	1845 1647
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

RECEIVED  
OCT 15 2002

112	GLENN et al., "Skin immunization made possible by cholera toxin," <i>Nature</i> , 391: 851 (1998).
114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <i>Biochemical and Biophysical Research Communications</i> , 122(3): 1131-1135 (1994).
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <i>Biochemical and Biophysical Research Communications</i> , 120(3): 885-890 (1994).
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> , 349:704-706 (1991).
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <i>Immunology</i> , 93:149-153 (1998).
237	GORTNER, <i>Outlines of Biochemistry</i> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <i>PNAS USA</i> , 93:427-432 (1996).
190	GRAVINA et al., "Amyloid $\beta$ Protein (A $\beta$ ) in Alzheimer's Disease," <i>J. Biol. Chem.</i> , 270(13):7013-7016 (1995).
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?", <i>TINS</i> , 23:114 (2000).
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <i>Vaccine</i> , 15(12/13): 1341-1343 (1997).
241	HAASS et al., "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <i>Nature</i> , 359(6393):322-5 (1992).
118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Brain Research</i> , 601:88-94 (1993).
182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <i>Int. J. Exp. Clin. Invest.</i> , 3:130-133 (1996).
119	HANES et al., "New advances in microsphere-based single-dose vaccines," <i>Advanced Drug Delivery Reviews</i> , 28: 97-119 (1997).
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <i>TINS</i> , 20(4): 154-159 (1997).
121	HARDY, John, "New Insights into the Genetics of Alzheimer's Disease," <i>Annals of Med.</i> , 28:255-258 (1996).
255	HARIGAYA, et al., "Modified amyloid $\beta$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 211:1015-1022 (1995).
193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ /A4-protein," <i>Biochimica Biophysica Acta</i> , 1158:120-128 (1993).

Examiner  
Signature

*Guriq Basi*

Date  
Considered

5/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

16

### Complete If Known

Application Number

10/010942

Filing Date

December 6, 2001

First Named Inventor

Basi, Guriq *et al.*

Group Art Unit

1845 / 1647

Examiner Name

NICHOLS

Attorney Docket Number

ELN-002

RECEIVED

OCT 15 2002

229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2", <i>Immunology</i> , Vol. 78: 643-649 (1993).	1
177	HELMUTH, L., "Further Progress on a $\beta$ -Amyloid Vaccine," <i>Science</i> , 289:375 (2000).	1
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <i>Eur. J. Biochem.</i> , 201:61-69 (1991).	1
122	HSIAO et al., "Correlative Memory Deficits, $A\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <i>Science</i> , 274: 99-102 (1996).	1
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994).	1
474	<del>Human Immunology &amp; Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).</del>	1
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <i>N. E. J. Medicine</i> , 333(19):1283-1284 (1995).	1
256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- $\beta$ protein monoclonal antibody," <i>Lab. Invest.</i> , 57:446-449 (1987).	1
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <i>J. Neuroimmunology</i> , 24:173-182 (1989).	1
192	IWATSUBO et al., "Visualization of $A\beta$ 42(43) and $A\beta$ 40 in Senile Plaques with End-Specific $A\beta$ Monoclonals: Evidence That an Initially Deposited Species Is $A\beta$ 42(43)," <i>Neuron</i> , 13:45-53 (1994).	1
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <i>Immun. Rev.</i> , 62: 185-216 (1982).	1
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <i>Brain Research Protocols</i> , 2:23-30 (1997).	1
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <i>Am. J. of Pathology</i> 138:373-384 (1991).	1
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).	1
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1996).	1
128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).	1
258	KIDA, et al., "Early amyloid- $\beta$ deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <i>Neuroscience Letters</i> , 193:105-108 (1995).	1
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the $\beta$ A4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	1

INT. B. 100V 00 (1222) 5007

Examiner  
Signature


Date  
Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0697-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

10

of

16

### Complete If Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq <i>et al.</i>
Group Art Unit	1645 Ka47
Examiner Name	NICITOLS
Attorney Docket Number	ELN-002

RECEIVED  
OCT 15 2002  
CENTER 1600/2800

129	LAMPERT-ETCHELLS <i>et al.</i> , "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <i>Neurodegeneration</i> , 2:111-121 (1993).
130	LANGER, "New Methods of Drug Delivery," <i>Science</i> , 249: 1527-1532 (1990).
131	LANNFELT <i>et al.</i> , "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behavioural Brain Res.</i> , 57:207-213 (1993).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <i>Curr. Ops. in Chemical Biology</i> , 1:260-267 (1997).
132	LEMERE <i>et al.</i> , "Mucosal Administration of A $\beta$ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," <i>Society for Neuroscience Abstracts</i> , vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).
260	LEMERE, <i>et al.</i> , "Nasal A $\beta$ treatment induces anti-A $\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <i>Annals of the NY Acad. Sci.</i> , 920:328-331 (2000).
184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milleu," <i>Biochem. Mol. Biol. Int.</i> , 43(3):801-811 (1997).
133	LIVINGSTON <i>et al.</i> , "The Hepatitis B Virus-Specific CTL Responses Induced In Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> , 159: 1383-1392 (1997).
134	LOPEZ <i>et al.</i> , "Serum auto-antibodies in Alzheimer's disease," <i>Acta. Neurol. Scand.</i> , 84:441-444 (1991).
218	MAJOCHA <i>et al.</i> , "Development of a Monoclonal Antibody Specific for $\beta$ A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <i>The J. of Nuclear Med.</i> , 33:2184-2189 (1992).
261	MAK, <i>et al.</i> , "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <i>Brain Research</i> , 667:138-142 (1994).
263	MANN, <i>et al.</i> , "Amyloid $\beta$ protein (A $\beta$ ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of A $\beta$ <sub>42(43)</sub> ," <i>Annals of Neurology</i> , 40:149-158 (1996).
262	MANN, <i>et al.</i> , "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <i>Neuroscience Letters</i> , 196:105-108 (1995).
217	MASTERS <i>et al.</i> , "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <i>Proc. Natl. Acad. Sci. USA</i> , 82:4245-4249 (1985).
135	MCGEE <i>et al.</i> , "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro. Encap.</i> , 14(2): 197-210 (1997).
264	McGeer, <i>et al.</i> , "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <i>J. of Neuroscience Res.</i> , 31:428-442 (1992).
238	MCNEAL <i>et al.</i> , "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <i>Virology</i> , 243:158-166 (1998).
138	MEDA <i>et al.</i> , "Activation of microglial cells by $\beta$ -amyloid protein and interferon- $\gamma$ ," <i>Nature</i> , 374:647-650 (1995).

Examiner  
Signature

Date


Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

11

of

16

### Complete if Known

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq <i>et al.</i>
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	ELN-002

RECEIVED  
OCT 15 2002  
ECH CENTER 1600 2800

265	Mena, et al., "Monitoring pathological assembly of tau and $\beta$ -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
206	MORI et al., "Mass Spectrometry of Purified Amyloid $\beta$ Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989).
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of $\beta$ -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995).
268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid $\beta$ protein (A $\beta$ ) subtypes (A $\beta$ 40 and A $\beta$ 42(43)) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995).
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).
235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acta</u> , 104:480-486 (1965).
280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).
141	PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).
269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1998).
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994).
143	QUON et al., "Formation of $\beta$ -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).

Examiner  
Signature

*G. Uriq*

Date  
Considered

5/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23

O I P E  
OCT 07 2002  
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 16

Complete if Known

Application Number 10/010942

Filing Date December 6, 2001

First Named Inventor Basi, Gurig et al.

Group Art Unit 1645 1647

Examiner Name NICHOLS

Attorney Docket Number ELN-002

OCT 15 2002

RECEIVED

TECH CENTER 1600/2900  
JAN 10 2002  
DISCNO 7

CSW	145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	
	<del>144</del>	<del>RASO, V.A., Grant application # 1 R43 AG1 5748-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).</del>	
	<del>104</del>	<del>RASO, V.A., Grant application # 1 R43 AG1 5748-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).</del>	
	146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	
	147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	
	209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
	189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
	194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	
	278	SAITO et al., "Vector-mediated delivery of $^{125}$ I-labeled $\beta$ -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A $\beta^{1-40}$ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995).	
	278	SAITOH, N. and K. IMAI, "Immunological analysis of Alzheimer's disease using anti- $\beta$ -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).	
	277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).	
	148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	
	178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	
	270	SCHENK, et al., " $\beta$ -peptide immunization," <u>Arch. Neurol.</u> , 57:934-938 (2000).	
	150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	
	151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	
✓	149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	
CSW	155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	

Examiner  
Signature

Nichols

Date  
Considered

5/14/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23



01 PE JCS  
OCT 07 2002  
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 16

### Complete If Known

Application Number 10/010942  
Filing Date December 6, 2001  
First Named Inventor Basi, Guriq et al.  
Group Art Unit 1645-1647  
Examiner Name NICHOLS  
Attorney Docket Number ELN-002

OCT 15 2002  
TECH CENTER 1600/2930

RECEIVED

COPIES OF DISCLOSURE

CSN	152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	
	153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	
	154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	
	156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	
	157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	
	158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	
	185	SOLOMON and GOLDSTEIN, "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	
	<del>186</del>	<del>SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).</del>	
	159	SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997).	
	160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996).	
	<del>161</del>	<del>SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).</del>	
	<del>162</del>	<del>SOLOMON, B., "New Approach Towards Fast Induction of Anti <math>\beta</math>-Amyloid Peptide Immune Response," Department of Molecular Microbiology &amp; Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown).</del>	
	179	SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	
	271	ST. GEORGE-HYSLOP, PETER H. and DAVID A. WESTAWAY, "Antibody clears senile plaques," <u>Nature</u> , 40:116-117 (1989).	
	183	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum</i> Malaria," <u>N. Engl. J. Med.</u> , 338(2): 88-91 (1997).	
	184	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	
↓	272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid $\beta$ -peptide as modeled with N-terminal decapeptide fragments," <u>Int. J. Peptide Protein Res.</u> , 47:289-296 (1996).	
CSN	185	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <u>European J. Pharmacology</u> , 352:135-142 (1998).	

Examiner  
Signature

G. Nichols


Date  
Considered

5/14/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23



Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

14

of

16

## Complete if Known

Application Number

10/010942

Filing Date

December 6, 2001

First Named Inventor

Basi, Gurig *et al.*

Group Art Unit

1045-1687

Examiner Name

NICHOLS

Attorney Docket Number

ELN-002

RECEIVED

OCT 15 2002

273	THORSETT, E.D. and L.H. LATIMER, "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000).
276	TJERNBERG <i>et al.</i> , "Arrest of $\beta$ -amyloid fibril formation by a pentapeptide ligand," <i>Journal of Biological Chemistry</i> , 271:8545-8548 (1996).
166	TRIEB <i>et al.</i> , "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).
167	VAN GOOL <i>et al.</i> , "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neuroscience Letters</i> , 172:122-124 (1994).
168	VERBEEK <i>et al.</i> , "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994).
169	WALKER <i>et al.</i> , "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).
274	WEINER <i>et al.</i> , "Nasal administration of amyloid- $\beta$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <i>Annals of Neurology</i> , 48:567-579 (2000).
171	WEINER <i>et al.</i> , "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).
172	WEISSMANN <i>et al.</i> , "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <i>Curr. Opin. Neurobiol.</i> , 7: 695-700 (1997).
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <i>J. Food Drug Analysis</i> , 6(2):465-476 (1998).
170	WENGENACK <i>et al.</i> , "Targeting Alzheimer amyloid plaques <i>in vivo</i> ," <i>Nature Biotech.</i> , 18:868-872 (2000).
223	<del>Alcon Research Foundation, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologics", U.S. Govt. Res. Develop. Rep., 70(24), 56, (Publication date unknown.)</del>
219	WONG <i>et al.</i> , "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <i>PNAS USA</i> , 82:8729-8732 (1985).
173	WOOD <i>et al.</i> , "Amyloid precursor protein processing and A $\beta$ 42 deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS USA</i> , 94: 1550-1555 (1997).
275	WU, <i>et al.</i> , "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier <i>in vivo</i> with a monoclonal antibody to the human insulin receptor," <i>J. Clin. Invest.</i> , 100:1804-1812 (1997).
292	YAMAGUCHI <i>et al.</i> , "Diffuse plaques associated with astroglial amyloid $\beta$ protein, possibly showing a disappearing stage of senile plaques," <i>Acta Neuropathol.</i> , 95:217-222 (1998).
290	YOUNKIN, "Amyloid $\beta$ vaccination: reduced plaques and improved cognition," <i>Nature Medicine</i> , 7:18-19 (2001).

INITIALS: DO NOT DISCARD


Examiner Signature		Date Considered	5/14/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
PA 3147648 v23





Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 15 of 16

**Complete if Known**

Application Number	10/010942
Filing Date	December 6, 2001
First Named Inventor	Basi, Guriq <i>et al.</i>
Group Art Unit	1645-147
Examiner Name	NICHOLS
Attorney Docket Number	ELN-002

TECH CENTER 1600/2900

OCT 15 2002

RECEIVED

CDO	A1	Chen G, et al. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 2000 Dec 21;28;408(6815):975-9	
	A2	Janus C, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000 Dec 21;28;408(6815):979-82	
	A3	Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev. 1997 Oct;77(4):1081-132	
	A4	Merluzzi S, et al. Humanized antibodies as potential drugs for therapeutic use. Adv Clin Path. 2000 Apr;4(2):77-85.	
	A5	Morgan D, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000 Dec 21;28;408(6815):982-5	
	A6	Schenk D, et al. Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier. DNA Cell Biol. 2001 Nov;20(11):679-81	
	A7	Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 1998 Nov;8(11):447-53	
	A8	Sigurdsson EM, et al. In vivo reversal of amyloid-beta lesions in rat brain. J Neuropathol Exp Neurol. 2000 Jan;59(1):11-17	
	A9	Sinha S, et al. Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 2000;920:206-8	
✓	A10	Soto C, et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med. 1998 Jul;4(7):822-8	
CDO	A11	Vehmas AK, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPsw/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. DNA Cell Biol. 2001 Nov;20(11):713-21	

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
CDO	A12	5,593,848	—	Schenk et al.	01-14-1997	—
CDO	A13	5,837,872	—	Schenk et al.	11-17-1998	—

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CDO	A14	—	WO 00/72876	A2, A3	—	12-07-2000	—	—
CDO	A15	—	WO 00/72880	A2, A3	—	12-07-2000	—	—

Examiner Signature

Date Considered

5/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23

PIPE  
OCT 07 2002  
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16 of 16

## Complete If Known

Application Number 10/010942  
Filing Date December 6, 2001  
First Named Inventor Basi, Guriq *et al.*  
Group Art Unit 1845 1647  
Examiner Name NICHOLS  
Attorney Docket Number ELN-002

TECH CENTER 600/2900

OCT 15 2002

RECEIVED

B1	Du Y, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001 Sep 11;57(5):801-5.	
B2	Small DH, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci. 2001 Aug;2(8):595-8	

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code 2 (if known)			
CD	B3	US 2001/0102261	A1	Raso	08-01-2002	
CD	B4	US 2002/0136718	A1	Raso	09-26-2002	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 9
		Office 3	Number 4	Kind Code 5 (if known)				
CD	B5		WO 00/77178	A1		12-21-2000		

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code 2 (if known)			
CD	B6	09/724,842		Chalifour et al.	N/A	

Examiner Signature

*G. Miller*

Date Considered

5/14/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3147648 v23

NOT PRINTED; DISCARDED